{
    "ticker": "ENLV",
    "name": "Enlivex Therapeutics Ltd.",
    "description": "Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing innovative therapies to treat severe and life-threatening conditions. The company specializes in the development of its proprietary drug candidate, Allocetra, which is designed to restore immune balance in patients suffering from various conditions, including sepsis and other critical illnesses. Founded in 2018, Enlivex aims to address significant unmet medical needs by harnessing the power of the immune system through its advanced scientific research and development efforts. Allocetra has shown promise in clinical trials for its ability to modulate immune responses, potentially leading to improved outcomes for patients with severe infections and inflammatory diseases. Enlivex is committed to advancing its clinical programs and expanding its therapeutic applications, focusing on enhancing patient care and outcomes. With a dedicated team of experts and strong partnerships within the pharmaceutical and biotechnology sectors, Enlivex is positioned to make a meaningful impact on the treatment landscape for critically ill patients. The company's mission is to innovate and provide breakthrough therapies that can change the lives of patients and their families worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Nesher, Israel",
    "founded": "2018",
    "website": "https://www.enlivextx.com",
    "ceo": "Eran G. Gertner",
    "social_media": {
        "twitter": "https://twitter.com/EnlivexTx",
        "linkedin": "https://www.linkedin.com/company/enlivex-therapeutics-ltd"
    },
    "investor_relations": "https://www.enlivextx.com/investors",
    "key_executives": [
        {
            "name": "Eran G. Gertner",
            "position": "CEO"
        },
        {
            "name": "Arielle K. B. D. R. Kloss",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Allocetra"
            ]
        }
    ],
    "seo": {
        "meta_title": "Enlivex Therapeutics Ltd. | Innovative Immunotherapy Solutions",
        "meta_description": "Explore Enlivex Therapeutics Ltd., a leader in developing innovative immunotherapies for severe and life-threatening conditions. Learn about Allocetra and its impact on patient care.",
        "keywords": [
            "Enlivex",
            "Biotechnology",
            "Immunotherapy",
            "Allocetra",
            "Sepsis Treatment",
            "Critical Illness"
        ]
    },
    "faq": [
        {
            "question": "What is Enlivex known for?",
            "answer": "Enlivex is known for its innovative immunotherapy drug candidate, Allocetra, aimed at treating severe conditions like sepsis."
        },
        {
            "question": "Who is the CEO of Enlivex?",
            "answer": "Eran G. Gertner is the CEO of Enlivex Therapeutics Ltd."
        },
        {
            "question": "Where is Enlivex headquartered?",
            "answer": "Enlivex is headquartered in Nesher, Israel."
        },
        {
            "question": "What is Allocetra?",
            "answer": "Allocetra is Enlivex's proprietary drug candidate designed to modulate immune responses in critically ill patients."
        },
        {
            "question": "When was Enlivex founded?",
            "answer": "Enlivex was founded in 2018."
        }
    ],
    "competitors": [
        "CRTX",
        "CERS",
        "ALNY",
        "TGTX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "NVAX",
        "BMY"
    ]
}